SUSTANON-250 by Meditech is a pharmaceutical-grade multi-ester Testosterone blend combining Testosterone Propionate, Testosterone Phenylpropionate, Testosterone Isocaproate, and Testosterone Decanoate in a single oil-based injectable formulation at 250 mg/mL. The four-ester composition is a subject of clinical and pharmacological interest for its association with a multi-phase testosterone release profile, delivering both rapid-onset and sustained androgen availability within a single administration.
 
✔ Key Research Insights
Studied for its multi-phase pharmacokinetic profile, with testosterone propionate contributing rapid-onset androgen availability and phenylpropionate, isocaproate, and decanoate esters providing progressively extended sustained release in research subjects
Investigated for its effects on lean mass parameters and strength indices via androgen receptor activation in documented clinical observations
Researched for its influence on recovery markers and training adaptation across subject populations in anabolic research literature
Examined for its dual-action profile combining immediate and long-lasting testosterone release, associated with stable serum androgen concentrations and reduced administration frequency in pharmacokinetic research
Documented for its effects on protein synthesis, nitrogen retention, and erythropoietic stimulation across comparative testosterone research literature
Manufactured by Meditech to pharmaceutical-grade purity and potency standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: SUSTANON-250
Molecule: Testosterone Blend
Composition:
Testosterone Propionate: 30 mg/mL
Testosterone Phenylpropionate: 60 mg/mL
Testosterone Isocaproate: 60 mg/mL
Testosterone Decanoate: 100 mg/mL
Total Concentration: 250 mg/mL
Appearance: Oil-based solution
Packing: Sterile 10 mL vial or 10 x 1 mL ampoules
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
SUSTANON-250 delivers four testosterone esters simultaneously via intramuscular injection, each undergoing enzymatic hydrolysis at a distinct rate to release free testosterone into systemic circulation across a staggered multi-phase timeline in research subjects. Testosterone propionate, as the shortest-acting ester in the blend, undergoes rapid hydrolysis following administration, producing an early elevation of circulating free testosterone. Testosterone phenylpropionate contributes a short-to-medium release phase, extending initial androgenic activity beyond the propionate window. Testosterone isocaproate provides a medium-duration sustained release phase, while testosterone decanoate — as the longest-acting ester in the formulation — maintains prolonged plasma testosterone concentrations across the final and most extended phase of the dosing interval. The resulting composite pharmacokinetic profile spans from near-immediate onset through sustained activity across a prolonged inter-dose interval, minimizing serum concentration fluctuations associated with single-ester preparations. Documented downstream effects across research populations include androgen receptor activation in muscle tissue with associated influences on protein synthesis, nitrogen retention, and erythropoietic activity. As with all aromatizable testosterone formulations, conversion to estrogen via the aromatase enzyme has been documented in clinical observations, with estrogenic sequelae referenced in research literature as pharmacologically relevant considerations in multi-ester testosterone administration protocols.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade purity and consistency standards
Four-ester testosterone blend with a well-documented multi-phase pharmacokinetic rationale in comparative androgen research literature
Precise and consistent testosterone concentration per unit across both vial and ampoule formats
Available in both multi-dose vial and single-dose ampoule formats for clinical administration flexibility
Widely referenced in endocrinological and anabolic pharmacology research under the testosterone blend and Sustanon-250 designations